Picture EBD Group Biotech Showcase 2019 BTS San Francisco January DIC 600x60px
Document › Details

bioMérieux S.A.. (7/18/18). "Press Release: Second-Quarter 2018 Business Review".

Organisation Organisation bioMérieux S.A. (Euronext: BIM)
  Group Mérieux (Group)
Products Product in vitro diagnostics (IVD)
  Product 2 molecular diagnostics
Person Person Mérieux, Alexandre (Mérieux 201712– CEO at bioMérieux before Deputy CEO before VP Industrial Microbiology)

> Strong sales dynamic confirmed in second quarter, leading to sales up 10.4% over the first half at constant exchange rates and scope of consolidation:

>> €1,169 million in sales

>> Up 3.1% as reported

> Growth driven by robust molecular biology and microbiology lines and by industrial applications.

Alexandre Mérieux, Chairman and Chief Executive Officer, said: “After a first quarter in which sales were particularly high due to the flu season, the second quarter of 2018 was another period of strong sales performance for bioMérieux with organic growth of 8.4%. The Group’s balanced and diversified geographic footprint and its comprehensive offering based on three key technologies of in vitro diagnostics were major factors in its success in the second quarter.”

[ Full Release at ]

Record changed: 2018-08-22


Picture [LSUS] – The Business Web Portal 600x60px

More documents for Mérieux (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px

» top